Answers are grounded in this paper and cite their sources.
INTRODUCTION/OBJECTIVE: Pulmonary tuberculosis (TB) remains a major global health challenge owing to prolonged therapy, poor adherence, systemic toxicity, and multidrug- and extensively drug-resistant Mycobacterium tuberculosis (Mtb). This review evaluates recent advances in nanotechnology- enabled inhalable therapeutics for pulmonary TB, focusing on preclinical performance, clinical development, and patent activity. METHODS: Literature published during 2022-2025 was reviewed using PubMed, Scopus, Web of Science, and ClinicalTrials.gov.in Qualitative and quantitative evidence was synthesized for inhalable liposomes, dry powder inhalers, polymeric nanoparticles, solid lipid nanoparticles, nanomicelles, metal-organic frameworks, and related systems, emphasizing aerodynamic performance, drug loading, macrophage targeting, pulmonary retention, pharmacokinetics, antimicrobial efficacy, and safety. RESULTS: Inhalable nanocarriers typically have particle sizes ranging from 80 to 500 nm and mass median aerodynamic diameters ranging from 1 to 5 μm, which supports deep lung deposition. Encapsulation efficiencies of 70-90% have been reported for first- and second-line anti-TB drugs. These drugs have been shown to have 2-6 times higher concentrations in the lungs and are retained in the lungs for longer than conventional formulations. Preclinical studies have demonstrated enhanced targeting of macrophages, intracellular drug delivery, sustained release, and reduced systemic exposure. DISCUSSION: Despite encouraging preclinical findings, clinical translation remains limited by manufacturing scalability, long-term pulmonary toxicity, formulation and aerosolization variability, regulatory requirements, and insufficient clinical evidence. CONCLUSION: Nanotechnology-enabled inhalable therapeutics offer a promising approach to treating TB in the lungs. However, well-designed clinical trials, standardised inhalation protocols, long-term safety evaluations, and regulatory harmonisation are needed to establish their clinical efficacy and translational applicability.
No takes yet. Share an insight, caveat, or question.
Sahu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: